a better way to treat inflammation
Inapill is developing 1st-in-class, orally available small molecule therapeutics with superior efficacy for improved treatment of inflammatory, autoimmune, and age-related diseases.
Based on our cutting-edge immunometabolism research featured in
Current anti-inflammatory biologics have poor efficacy & patient compliance - why?
Cytokine redundancy – blocking one pro-inflammatory cytokine is not enough to stop disease progression driven by multiple pro-inflammatory factors
Anti-drug antibodies – biologics are proteins, meaning patient’s immune systems produce antibodies that block the action of these drugs
Expensive drugs require injection – ouch
of patients taking the leading anti-TNF therapy for rheumatoid arthritis develop drug resistance over time
50%
30%
TNF-⍺
of patients taking the leading anti-TNF therapy for rheumatoid arthritis don’t respond
Anti-hTNF-⍺
targeting immunometabolism
Our Approach
Inspired by research on sex differences in inflammation & autoimmune disease
prevalence in women vs. men, and new ways sex hormones protect both men and women from inflammation.
Our small molecule therapeutics work upstream on immune cell metabolism, simultaneously suppressing the production of multiple disease-driving cytokines by immune cells.
Simultaneously inhibits multiple pro-inflammatory cytokines
Tunes mitochondrial function
“Our mission is to create safe, oral small-molecule therapies that redefine how inflammation is treated.”
— Greg Timblin, Inapill Founder & CEO
Meet the Team
-
Greg Timblin, PhD
Founder & CEO
Dr. Timblin founded Inapill based on ideas from his research on the immunometabolic control of inflammation as a American Diabetes Association (ADA) Postdoctoral Scholar at UC Berkeley & UC San Francisco. He has led Inapill’s internal discovery of novel ways to therapeutically target disease-driving metabolic shifts in immune cells.
-
Eric Noel, PhD
Scientist, Protein Biochemist
Dr. Noel trained as a postdoctoral fellow at the Innovative Genomics Institute, founded by Nobel Laureate Dr. Jennifer Doudna at UC Berkeley. He brings deep expertise in CRISPR gene editing, protein biochemistry, and protein engineering. Dr. Noel is applying this expertise to drive Inapill’s small molecule drug discovery programs forward.
-
Kathleen Pestal, PhD
Scientist, Immunology
Dr. Pestal is an immunologist whose work spans inflammation, autoimmunity, and cancer. She earned her Ph.D. from the University of Washington, and completed postdoctoral training at UC Berkeley, where she received a Cancer Research Institute Irvington Fellowship. Dr. Pestal is applying her extensive knowledge of the immune system to to spearhead Inapill’s drug discovery efforts.
-
General Inception
Deep Tech Venture Studio
Inapill is supported by the therapeutic team at General Inception. With 20+ executives and decades of combined industry experience, including expertise in small molecule drug development.
Tenant Spotlight on Inapill: A Novel Approach to Interrupting Inflammation
⋆
Tenant Spotlight on Inapill: A Novel Approach to Interrupting Inflammation ⋆
